ESPERION INVESTORS NOTICE: Lieff Cabraser Reminds Investors of Deadline in Class Action Against Esperion Therapeutics, Inc.
February 23 2016 - 3:00PM
Business Wire
The law firm of Lieff Cabraser Heimann & Bernstein, LLP
reminds investors of the upcoming deadline to move for appointment
as lead plaintiff in securities class litigation brought on behalf
of investors who purchased the common stock of Esperion
Therapeutics, Inc. (“Esperion” or the “Company”) (Nasdaq: ESPR)
between August 18, 2015 and September 28, 2015, inclusive (the
“Class Period”).
If you purchased Esperion common stock during the Class Period,
you may move the Court for appointment as lead plaintiff by no
later than March 14, 2016. A lead plaintiff is a representative
party who acts on behalf of other class members in directing the
litigation. Your share of any recovery in the action will not be
affected by your decision of whether to seek appointment as lead
plaintiff. You may retain Lieff Cabraser, or other attorneys, as
your counsel in the action.
Esperion investors who wish to learn more about the action and
how to seek appointment as lead plaintiff should click here or
contact Sharon M. Lee of Lieff Cabraser toll-free at
1-800-541-7358.
Esperion’s lead product candidate is ETC-1002. The action
alleges that during the Class Period, defendants issued false and
misleading statements and failed to disclose that there was no
clear path to approval for ETC-1002, and that the U.S. Food and
Drug Administration (“FDA”) had encouraged the Company to initiate
a cardiovascular outcomes trial (“CVOT”) and that completion of a
CVOT could be necessary prior to approval of ETC-1002.
On August 17, 2015 Esperion disclosed material events from a
meeting with the FDA. The Company claimed that they were told that
no CVOT would be necessary for the approval of ETC-1002 and that
there was a “clear regulatory path forward for development and
approval of ETC-1002.”
On September 28, 2015, Esperion disclosed the truth about the
August 2015 meeting with the FDA, admitting that the FDA encouraged
Esperion to complete a CVOT and that it may be necessary to have a
completed CVOT for the drug’s approval. Following this news, the
price of Esperion common stock fell $16.76 per share, or 47.7%, to
close at $18.33 on September 29, 2015.
About Lieff Cabraser
Lieff Cabraser Heimann & Bernstein, LLP is a nationally
recognized law firm committed to advancing investor rights and
promoting corporate responsibility.
For thirteen years, the National Law Journal has selected Lieff
Cabraser as one of the top plaintiffs’ law firms in the nation.
Best Lawyers and U.S. News have also named Lieff Cabraser as a “Law
Firm of the Year” each year the publications have given this award
to law firms.
For more information about Lieff Cabraser and the firm’s
representation of investors, please visit
http://www.lieffcabraser.com.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160223006781/en/
Source/Contact for Media Inquiries
Only:Lieff Cabraser Heimann & Bernstein, LLPSharon M.
Lee, 800-541-7358
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024